| Literature DB >> 33577765 |
Philip J M Brouwer1, Mitch Brinkkemper1, Pauline Maisonnasse2, Nathalie Dereuddre-Bosquet2, Marloes Grobben1, Mathieu Claireaux1, Marlon de Gast1, Romain Marlin2, Virginie Chesnais3, Ségolène Diry3, Joel D Allen4, Yasunori Watanabe5, Julia M Giezen1, Gius Kerster1, Hannah L Turner6, Karlijn van der Straten1, Cynthia A van der Linden1, Yoann Aldon1, Thibaut Naninck2, Ilja Bontjer1, Judith A Burger1, Meliawati Poniman1, Anna Z Mykytyn7, Nisreen M A Okba7, Edith E Schermer1, Marielle J van Breemen1, Rashmi Ravichandran8, Tom G Caniels1, Jelle van Schooten1, Nidhal Kahlaoui2, Vanessa Contreras2, Julien Lemaître2, Catherine Chapon2, Raphaël Ho Tsong Fang2, Julien Villaudy9, Kwinten Sliepen1, Yme U van der Velden1, Bart L Haagmans7, Godelieve J de Bree10, Eric Ginoux3, Andrew B Ward6, Max Crispin4, Neil P King8, Sylvie van der Werf11, Marit J van Gils1, Roger Le Grand12, Rogier W Sanders13.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.Entities:
Keywords: B cells; COVID-19; SARS-CoV-2; antibodies; immunity; macaques; nanoparticles; protection; vaccine
Mesh：
Substances：
Year: 2021 PMID： 33577765 PMCID： PMC7834972 DOI： 10.1016/j.cell.2021.01.035
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582